What is Zepbound?

What is Zepbound?

Zepbound is the brand name for tirzepatide when used for chronic weight management. Approved by the FDA in November 2023, it’s the same active ingredient as Mounjaro but approved specifically for obesity and overweight.

How is Zepbound Different from Mounjaro?

Both medications contain tirzepatide:

Feature	Zepbound	Mounjaro
Approved For	Weight management	Type 2 diabetes
Dose Range	2.5-15 mg weekly	2.5-15 mg weekly
FDA Approval	November 2023	May 2022

How Does Zepbound Work?

Zepbound is a dual GIP/GLP-1 receptor agonist that works through multiple mechanisms:

1. Reduces appetite through brain signaling
2. Increases satiety so you feel full faster and longer
3. Slows gastric emptying to extend fullness after meals
4. Improves insulin sensitivity as a metabolic benefit

The dual-receptor activity (targeting both GIP and GLP-1) may explain why tirzepatide produces greater weight loss than GLP-1-only medications in clinical trials.

Who is Zepbound Approved For?

FDA-Approved Indication

Adults with:

• Obesity (BMI of 30 or higher), OR
• Overweight (BMI of 27 or higher) with at least one weight-related condition (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Not Approved For

• Type 2 diabetes (use Mounjaro)
• Pediatric use (not yet approved)
• Cosmetic weight loss without medical indication

What Does the Research Show?

The SURMOUNT clinical trials showed substantial weight loss:

Trial	Population	Weight Loss (15 mg)
SURMOUNT-1	Obesity without diabetes	22.5% (~52 lbs average)
SURMOUNT-2	Obesity with type 2 diabetes	15.7%
SURMOUNT-3	After intensive lifestyle intervention	26.6%
SURMOUNT-4	Weight maintenance study	Maintained vs regain with placebo

These results represent some of the highest weight loss seen in obesity medication trials.

Key Facts

Fact	Detail
Administration	Once weekly subcutaneous injection
Titration	Start at 2.5 mg, increase every 4 weeks
Maintenance Doses	5 mg, 10 mg, or 15 mg
Trial Duration	72-88 weeks in pivotal studies

Common Side Effects

• Nausea (most common, usually temporary)
• Diarrhea
• Vomiting
• Constipation
• Injection site reactions

Side effects are generally mild to moderate and decrease over time, especially with gradual dose titration.

Important Considerations

Zepbound carries a boxed warning about thyroid C-cell tumors found in rodent studies. It should not be used by people with:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2

---

This guide is for educational purposes only. Zepbound is a prescription medication requiring medical supervision.